Indonesia Anti Aging Therapeutics Market Report 2022 to 2030

Indonesia Anti Aging Therapeutics Market Analysis

$ 3999

Indonesia's anti-ageing therapeutics market is projected to grow from $4 Mn in 2022 to $12 Mn in 2030 with a CAGR of 16.53% for 2022-2030. The market expansion is attributed to the growing elderly population and supportive government policies in Indonesia. The Indonesia anti-ageing therapeutics market is segmented by product, treatment, target group, type of ageing, type of molecules, mechanism of action, ingredient, and distribution channel. Some of the key players in the market include Asa Rén, PT Mitra Asiatek Biosensor, and Procter & Gamble.

ID: IN10IDPH030 CATEGORY: Pharmaceuticals GEOGRAPHY: Indonesia AUTHOR: Parul Choudhary

Buy Now

Indonesia Anti-Aging Therapeutics Market Executive Summary

Indonesia's anti-ageing therapeutics market is projected to grow from $4 Mn in 2022 to $12 Mn in 2030 with a CAGR of 16.53% for 2022-30. From the overall health budget allocation of $11 Bn for the upcoming year, the Indonesian ministry has put aside a budget of $5.96 Bn for health transformation in 2023. $0.39 Bn will be used to transform basic services through public awareness campaigns, primary and secondary preventative measures, and boosting their capacity and capabilities. Additionally, $1.2 Bn will be allocated for the transformation of referral services through enhancements to intermediate and tertiary services' accessibility and quality. $96 Mn is allocated for the health security system in order to strengthen disaster preparedness and the resiliency of the pharmaceutical and medical device industries. The minister continued by saying that $3.2 Bn will also be set aside in the budget to support the transformation of the medical funding system, which aims to prioritize accessibility, sufficiency, and sustainability as well as fairness in allocation and effective and efficient utilization.

The hallmarks of aging are the main focus of aging studies in the geroscience sector. Eight characteristics, such as stem cell failure, inflammation, senescence, and others, characterize aging. Senescence is the process by which cell ages and permanently stops dividing but does not die," according to the National Cancer Institute (NCI). The majority of medicines currently being researched in Indonesia for their benefits on healthy aging or anti-aging are modified versions of widely available FDA-approved medications. For instance, the diabetes medication metformin will be examined for its impacts on preventing age-related conditions like cardiovascular disease, cancer, impaired cognition, and mortality in the Targeting Aging with Metformin (TAME) Trial, a set of six-year studies. Well-known drugs like metformin and rapamycin are already being evaluated for off-label usage based on preclinical research for their impact on aging due to their accepted safety profile and cost-effectiveness. Different laboratories have discovered unique methods to monitor and quantify aging within these hallmarks. The flavonoid quercetin and drugs like Novartis' Sprycel (dasatinib) show significant promise for treating cellular senescence. Sprycel and quercetin are typically given to patients for their anti-inflammatory and effects on chronic myeloid leukemia, respectively.

Indonesia Anti Aging Therapeutics Market

Market Dynamics

Market Growth Drivers

The market is primarily driven by two factors: increasing demand for personalized, accurate, preventative, and participatory aging therapies. As a result, as the elderly population grows, so does the demand for anti-aging treatments.

The population of Indonesia is aging rapidly, with the proportion of people 65 and older projected to triple by 2050. As people seek to maintain their health and vitality as they age, this demographic change is likely to increase demand for anti-aging therapeutics. More potent anti-aging treatments are now feasible thanks to recent developments in anti-aging technology, such as stem cell therapy, gene therapy, and nanotechnology. The National Health Insurance program and the Healthy Indonesia program are just two of the initiatives the Indonesian government has initiated to support healthy aging. These efforts will probably open doors for anti-aging businesses and stimulate the Indonesia anti-aging therapeutics market expansion.

Market Restraints

Affordability for those with lower incomes may be hampered by the cost of anti-aging treatments and therapies. This might slow the Indonesia anti-aging therapeutics market expansion, especially among lower-income groups. Even though the public's knowledge of anti-aging goods and services is expanding, a sizable %age of people are still unaware of the advantages of such treatments. This might reduce the desire for anti-aging pharmaceuticals. The prevalence of herbal remedies and traditional medications in Indonesia may reduce the demand for anti-aging therapeutics among people who would rather use these alternatives.

Competitive Landscape

Key Players

DeBio Network (IDN)
Syngenta Indonesia (IDN)
Formulatrix Indonesia (IDN)
Asa Rén (IDN)
PT Mitra Asiatek Biosensor (IDN)
Procter & Gamble
Shiseido
Estée Lauder
Lumenis
Alma Lasers
Cynosure
Beiersdorf
Solta Medical

Healthcare Policies and Regulatory Landscape

The National Agency of Drug and Food Control (BPOM), which is a division of the Ministry of Health, is the regulatory agency in charge of regulating the use and trading of anti-aging medications in Indonesia. The safety, effectiveness, and purity of pharmaceuticals in Indonesia, including anti-aging medications, are the responsibility of BPOM. It controls the marketing, distribution, and registration of pharmaceuticals, including anti-aging medications, and it keeps track of their use to ensure their effectiveness and safety. The Indonesian National Agency for Health Technology Assessment (Badan Penilaian Teknologi Kesehatan, or BPTK), which the Indonesian government also created, evaluates the clinical advantages and cost-effectiveness of new health technologies, such as anti-aging medications. In order to make recommendations to the Ministry of Health regarding the adoption and use of novel health technologies, BPTK's job is to assess the clinical efficacy, safety, and economic implications of such technologies. This guarantees that the population of Indonesia has access to novel anti-aging medications that are not only effective and safe but also affordable. Overall, to ensure the safety, effectiveness, and accessibility of anti-aging medications in Indonesia, the National Agency for Drug and Food Control (BPOM) and the Indonesian National Agency for Health Technology Assessment (BPTK) play significant roles in the regulation of their use and dissemination.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Anti-Aging Therapeutics Market Segmentation

By Product (Revenue, USD Billion):

Anti-Wrinkle
Hair Color
Ultraviolet (UV) Absorption
Anti-Stretch Mark
Others

By Treatment (Revenue, USD Billion):

Hair Restoration
Anti-Pigmentation
Adult Acne Therapy
Breast Augmentation
Liposuction
Chemical Peel
Others

By Target Group (Revenue, USD Billion):

Male
Female

By Type of Aging (Revenue, USD Billion):

Cellular Aging
Immune Aging
Metabolic Aging
Others

By Type of Molecules (Revenue, USD Billion):

Biologics
Small Molecules

By Mechanism of Action (Revenue, USD Billion):

Senolytic
Cell Regeneration
mTOR inhibitor/Modulator
AMP-kinase/AMP Activator
Mitochondria Inhibitor/Modulator
Others

By Ingredient (Revenue, USD Billion):

Retinoid
Hyaluronic Acid
Alpha Hydroxy Acid
Others

By Distribution Channel (Revenue, USD Billion):

Pharmacies
Stores
Online Stores

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.